6 completed. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Abrocitinib 200 mg: new trials by email Literature Review of Abrocitinib 200 mg trials Research Report on Abrocitinib 200 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Abrocitinib 200 mg, Abrocitinib 100 mg, Placebo - Chronic Hand Eczema | Phase 2 | Completed | Innovaderm Research Inc. | 82 | 2024-05-31 | 2026-02-03 |
| Janus Kinase Inhibition in Granuloma Annulare Abrocitinib 200 mg - Granuloma Annulare | Phase 2 | Completed | William Damsky | 10 | 2023-10-27 | 2026-10-07 |
| Janus Kinase Inhibition in Sarcoidosis Abrocitinib 200 mg - Sarcoidosis | Phase 2 | Completed | Yale University | 10 | 2023-06-01 | 2026-09-21 |
| A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India Abrocitinib 100 mg, Abrocitinib 200 mg - Atopic Dermatitis | Phase 3 | Completed | Pfizer | 200 | 2022-07-16 | 2024-10-15 |
| Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Abrocitinib 200 mg, Dupilumab 300 mg - Atopic Dermatitis | Phase 3 | Completed | Pfizer | 727 | 2020-06-11 | 2022-07-08 |
| Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo - Dermatitis, Atopic | Phase 3 | Completed | Pfizer | 3166 | 2018-03-08 | 2026-01-15 |
Dermatitis, Atopic (4) · Eczema (3) · Granuloma Annulare (1) · Inhibition, Psychological (1) · Sarcoidosis (1)
Pfizer (3) · Innovaderm Research Inc. (1) · William Damsky (1) · Yale University (1)
United States (4) · Canada (3) · Poland (3) · Australia (2) · Bulgaria (2) · Chile (2) · Finland (2) · Germany (2) · Hungary (2) · Italy (2) · Latvia (2) · Slovakia (2) · South Korea (2) · Spain (2) · Taiwan (2)
William Damsky, M.D. (2) · Robert Bissonnette, MD (1)
PMID 39903335, PMID 42162528, PMID 42365219, PMID 34406619, PMID 35871814, PMID 37254941, PMID 39104653, PMID 40028832, PMID 40987931, PMID 42084697, PMID 42844558
2019 (1), 2023 (1)